282 related articles for article (PubMed ID: 15562367)
1. Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis.
Guaraldi G; Orlando G; Madeddu G; Vescini F; Ventura P; Campostrini S; Mura MS; Parise N; Caudarella R; Esposito R
HIV Clin Trials; 2004; 5(5):269-77. PubMed ID: 15562367
[TBL] [Abstract][Full Text] [Related]
2. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
[TBL] [Abstract][Full Text] [Related]
3. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
McComsey GA; Kendall MA; Tebas P; Swindells S; Hogg E; Alston-Smith B; Suckow C; Gopalakrishnan G; Benson C; Wohl DA
AIDS; 2007 Nov; 21(18):2473-82. PubMed ID: 18025884
[TBL] [Abstract][Full Text] [Related]
4. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.
Biermasz NR; Hamdy NA; Janssen YJ; Roelfsema F
J Clin Endocrinol Metab; 2001 Jul; 86(7):3079-85. PubMed ID: 11443170
[TBL] [Abstract][Full Text] [Related]
5. Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection.
Mondy K; Powderly WG; Claxton SA; Yarasheski KH; Royal M; Stoneman JS; Hoffmann ME; Tebas P
J Acquir Immune Defic Syndr; 2005 Apr; 38(4):426-31. PubMed ID: 15764959
[TBL] [Abstract][Full Text] [Related]
6. Prevention of glucocorticoid-induced osteoporosis in immunobullous diseases with alendronate: a randomized, double-blind, placebo-controlled study.
Tee SI; Yosipovitch G; Chan YC; Chua SH; Koh ET; Chan YH; Tan SS; Tsou IY; Tan SH
Arch Dermatol; 2012 Mar; 148(3):307-14. PubMed ID: 22105813
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group.
Schnitzer T; Bone HG; Crepaldi G; Adami S; McClung M; Kiel D; Felsenberg D; Recker RR; Tonino RP; Roux C; Pinchera A; Foldes AJ; Greenspan SL; Levine MA; Emkey R; Santora AC; Kaur A; Thompson DE; Yates J; Orloff JJ
Aging (Milano); 2000 Feb; 12(1):1-12. PubMed ID: 10746426
[TBL] [Abstract][Full Text] [Related]
8. Effect of a short-term treatment with alendronate on bone density and bone markers in patients with central diabetes insipidus.
Pivonello R; Faggiano A; Di Somma C; Klain M; Filippella M; Salvatore M; Lombardi G; Colao A
J Clin Endocrinol Metab; 1999 Jul; 84(7):2349-52. PubMed ID: 10404801
[TBL] [Abstract][Full Text] [Related]
9. Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis.
Planas J; Trilla E; Raventós C; Cecchini L; Orsola A; Salvador C; Placer J; Encabo G; Morote J
BJU Int; 2009 Dec; 104(11):1637-40. PubMed ID: 19549260
[TBL] [Abstract][Full Text] [Related]
10. [Alendronate in postmenopausal women with osteopenia and osteoporosis: effects on bone mineral density during treatment and after withdrawal].
Jiang Y; Li M; Xia W; Xing X; Yu W; Tian J; Meng X; Zhou X
Zhonghua Yi Xue Za Zhi; 2002 Sep; 82(18):1254-6. PubMed ID: 12425805
[TBL] [Abstract][Full Text] [Related]
11. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
Barone A; Giusti A; Pioli G; Girasole G; Razzano M; Pizzonia M; Palummeri E; Bianchi G
J Am Geriatr Soc; 2007 May; 55(5):752-7. PubMed ID: 17493196
[TBL] [Abstract][Full Text] [Related]
12. [Clinical application of alendronate for osteoporosis/osteopenia secondary to hyperthyroidism].
Yang LJ; Shen FX; Zheng JC; Zhang HL
Zhongguo Gu Shang; 2012 Feb; 25(2):133-7. PubMed ID: 22577718
[TBL] [Abstract][Full Text] [Related]
13. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism.
Rossini M; Gatti D; Isaia G; Sartori L; Braga V; Adami S
J Bone Miner Res; 2001 Jan; 16(1):113-9. PubMed ID: 11149474
[TBL] [Abstract][Full Text] [Related]
14. Effect of alendronate on HIV-associated osteoporosis: a randomized, double-blind, placebo-controlled, 96-week trial (ANRS 120).
Rozenberg S; Lanoy E; Bentata M; Viard JP; Valantin MA; Missy P; Darasteanu I; Roux C; Kolta S; Costagliola D;
AIDS Res Hum Retroviruses; 2012 Sep; 28(9):972-80. PubMed ID: 22353022
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of combined treatment with alendronate (ALN) and eldecalcitol, a new active vitamin D analog, compared to that of concomitant ALN, vitamin D plus calcium treatment in Japanese patients with primary osteoporosis.
Sakai A; Ito M; Tomomitsu T; Tsurukami H; Ikeda S; Fukuda F; Mizunuma H; Inoue T; Saito H; Nakamura T;
Osteoporos Int; 2015 Mar; 26(3):1193-202. PubMed ID: 25592133
[TBL] [Abstract][Full Text] [Related]
16. Different impact of NNRTI and PI-including HAART on bone mineral density loss in HIV-infected patients.
Madeddu G; Spanu A; Solinas P; Babudieri S; Calia GM; Lovigu C; Mannazzu M; Nuvoli S; Piras B; Bagella P; Mura MS; Madeddu G
Eur Rev Med Pharmacol Sci; 2015 Dec; 19(23):4576-89. PubMed ID: 26698255
[TBL] [Abstract][Full Text] [Related]
17. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
Murphy MG; Weiss S; McClung M; Schnitzer T; Cerchio K; Connor J; Krupa D; Gertz BJ;
J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study.
Orwoll ES; Miller PD; Adachi JD; Brown J; Adler RA; Kendler D; Bucci-Rechtweg C; Readie A; Mesenbrink P; Weinstein RS
J Bone Miner Res; 2010 Oct; 25(10):2239-50. PubMed ID: 20499357
[TBL] [Abstract][Full Text] [Related]
19. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
Giusti A; Barone A; Pioli G; Girasole G; Siccardi V; Palummeri E; Bianchi G
Nephrol Dial Transplant; 2009 May; 24(5):1472-7. PubMed ID: 19075192
[TBL] [Abstract][Full Text] [Related]
20. Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study.
Biermasz NR; Hamdy NA; Pereira AM; Romijn JA; Roelfsema F
Clin Endocrinol (Oxf); 2004 May; 60(5):568-75. PubMed ID: 15104559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
